


Interpretation of Syphilis Serology

Traditional Algorithm¹

1. Screen with non-treponemal test (RPR/VDRL).

2. Confirm reactive non-treponemal test with treponemal test.



*Primary syphilis and late, untreated syphilis are possible if RPR/VDRL are non-reactive—see below for recommended actions.

Non-Treponemal	Treponemal	Interpretations	Recommended Actions
Non-Reactive	Non-Reactive or Not Done	1. No syphilis 2. Early/incubating syphilis (too early to be detected by serology)	<ul style="list-style-type: none"> If syphilis is unlikely, no further action is needed. If early syphilis is suspected, run treponemal test (if not done initially) and repeat RPR/VDRL in 1-2 weeks; if either test is reactive, stage and treat for syphilis. If concerned for early syphilis (e.g., chancre present or known exposure), treat presumptively. If treating presumptively, repeat RPR/VDRL on day of treatment and, if non-reactive, again in 2-4 weeks to assess for seroconversion.
Non-Reactive	Reactive	1. Prior treated syphilis 2. Untreated syphilis	<ul style="list-style-type: none"> Treponemal tests (e.g., TP-PA) often stay reactive for life; if patient has history of adequate treatment for syphilis and no new exposures/symptoms, no further action is needed. If early syphilis is suspected (e.g., chancre present or known exposure), treat presumptively according to staging. If treating presumptively, repeat RPR/VDRL on day of treatment and, if non-reactive, again in 2-4 weeks to assess for seroconversion.

Non-Treponemal	Treponemal	Interpretations	Recommended Actions
Reactive	Non-Reactive	1. False-Positive RPR or VDRL	<ul style="list-style-type: none"> Likely a false-positive (not syphilis).² In pregnancy or patients at high-risk for syphilis, consider repeating serologic testing in 2-4 weeks, If unchanged, no action needed.³
	Reactive	<ol style="list-style-type: none"> Current syphilis Treated syphilis with residual RPR/VDRL titer 	<ul style="list-style-type: none"> If RPR/VDRL is newly reactive, stage and treat. If previously treated and sustained (≥ 2 weeks) four-fold rise in RPR/VDRL titer, manage as treatment failure versus re-infection.⁴ RPR/VDRL can remain reactive after treatment. If there is a four-fold decline within 12-24 months, treatment is considered adequate despite RPR/VDRL reactivity. Some treated patients may have a persistent, low-level RPR/VDRL titer. Re-treatment is not necessary in the absence of new exposure(s) and/or symptom(s).

- The traditional algorithm starts with a non-treponemal test. If reactive, it is followed by a treponemal test.
- False-positive results are often observed in pregnancy and in patients with autoimmune disorders, Lyme disease, certain viral infections, injection drug use and other conditions.
- It is recommended that all pregnant women be screened for syphilis three times during pregnancy — at confirmation of pregnancy or at first prenatal encounter, again between 28-32-weeks' gestation, and again at the time of delivery.
- For patients determined to have new syphilis or treatment failure, guidelines published by the Centers for Disease Control and Prevention should be used to determine treatment and follow-up recommendations.




Reverse-Sequence Algorithm¹

1. Screen with immunoassay treponemal assay.

2. Confirm reactive immunoassay with non-treponemal assay.

3. Clarify discordant EIA/CIA and RPR/VDRL results with second treponemal assay.



*Primary syphilis and late, untreated syphilis are possible if RPR/VDRL are non-reactive, see below for recommended actions.

Immunoassay	RPR/VDRL	TP-PA	Interpretations	Recommended Actions
Non-Reactive	Non-Reactive or Not Done	Non-Reactive or Not Done	1. Syphilis unlikely 2. Early/incubating syphilis (too early to be detected by serology)	<ul style="list-style-type: none"> If syphilis is unlikely—no further action is needed. If immunoassay is non-reactive but there is high clinical suspicion (such as chancre or known exposure), treat presumptively for early syphilis. If treating presumptively, obtain RPR/VDRL on day of treatment and, if non-reactive, again in 2-4 weeks to assess for seroconversion.
Reactive	Non-Reactive	Non-Reactive or Not Done	1. False-positive immunoassay 2. Early/incubating syphilis 3. Latent or prior syphilis (treated or untreated)	<ul style="list-style-type: none"> If no signs/symptoms and low risk for syphilis, most likely a false-positive immunoassay.² No further action needed. If concerned for early infection or in pregnant patients, re-screen in 2-4 weeks.³ If signs/symptoms or contact to early syphilis, treat presumptively. Repeat RPR/VDRL on day of treatment and, if non-reactive, again in 2-4 weeks to assess for seroconversion.



Immunoassay	RPR/VDRL	TP-PA	Interpretations	Recommended Actions
Reactive	Non-Reactive	Reactive	<ol style="list-style-type: none"> Latent or prior syphilis (treated or untreated) Early syphilis (prior to RPR/VDRL seroconversion) 	<ul style="list-style-type: none"> No further action needed if patient treated appropriately for syphilis in the past—assuming no new exposure/symptoms and a negative physical exam. If no symptoms and no known prior adequate treatment, treat presumptively for latent syphilis. If early syphilis is suspected (symptoms or known exposure), treat presumptively. Obtain RPR/VDRL on day of treatment and, if non-reactive, again in 2-4 weeks to assess for seroconversion.
	Reactive	Not Done or Reactive	<ol style="list-style-type: none"> Current syphilis Prior syphilis (treated or untreated) 	<ul style="list-style-type: none"> If RPR/VDRL is newly reactive, stage and treat. If previously treated and sustained (≥ 2 weeks) four-fold rise in RPR/VDRL titer, manage as treatment failure versus re-infection.⁴ If known prior adequate treatment for stage of infection and RPR/VDRL is declining appropriately (i.e., a four-fold decline within 12-24 months), no further action is needed. Some treated patients may have a persistent, low-level RPR/VDRL titer—re-treatment is not necessary in the absence of new exposure(s) and/or symptom(s).

- The reverse-sequence algorithm starts with an immunoassay detecting syphilis antibodies—which, if reactive—is followed by a quantitative RPR/VDRL. If there is a discrepancy between the immunoassay and RPR (one reactive, one non-reactive), a treponemal test (TP-PA) serves as the tiebreaker.
- False-positive immunoassays can occur with Lyme disease or non-syphilitic treponemal infections.
- It is recommended that all pregnant women be screened for syphilis three times during pregnancy— at confirmation of pregnancy or at first prenatal encounter and again between 28-32-weeks' gestation, and again at the time of delivery.
- For patients determined to have new syphilis or treatment failure, guidelines published by the Centers for Disease Control and Prevention should be used to determine treatment and follow-up recommendations.

